mTOR/AKT Inhibitors for Endometrial and Ovarian Cancer
Trial Summary
Will I have to stop taking my current medications?
The trial protocol does not specify if you need to stop taking your current medications. However, certain medications and substances are prohibited within specific wash-out periods, so it's best to discuss your current medications with the trial team.
What data supports the effectiveness of the drug AZD2014, AZD5363, Olaparib, Lynparza for endometrial and ovarian cancer?
Is olaparib safe for humans?
Olaparib has been studied in patients with advanced ovarian cancer, and while it offers benefits, it can also cause side effects. Common side effects include blood-related issues and other non-blood-related problems, but the specific details on safety are not fully detailed in the available studies.678910
What makes the drug AZD2014, AZD5363, and Olaparib unique for endometrial and ovarian cancer?
This drug combination targets the PI3K/AKT/mTOR pathway, which is often overactive in endometrial and ovarian cancers, offering a novel approach by potentially reducing tumor growth and resistance to other treatments. Unlike standard therapies, this combination includes mTOR inhibitors and Olaparib, a PARP inhibitor, which may enhance effectiveness in these cancers.134511
What is the purpose of this trial?
This phase Ib/II trial studies the side effects and best dose of olaparib and vistusertib (AZD2014) or olaparib and capivasertib (AZD5363) when given together in treating patients with endometrial, triple negative breast cancer, ovarian, primary peritoneal, or fallopian tube cancer that has come back (recurrent). Olaparib, vistusertib, and capivasertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Research Team
Shannon Westin, MD
Principal Investigator
M.D. Anderson Cancer Center
Eligibility Criteria
This trial is for patients with recurrent endometrial, ovarian, peritoneal, fallopian tube cancer or triple negative breast cancer. Participants must have a life expectancy over 4 months and be able to take oral meds. They should agree to use contraception and have specific blood levels within normal ranges. Those with other recent cancers or certain health conditions can't join.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive olaparib and either vistusertib or capivasertib in various dosing schedules over 28-day cycles
Follow-up
Participants are monitored for safety and effectiveness after treatment
Long-term follow-up
Participants are monitored for progression-free survival and response duration
Treatment Details
Interventions
- AZD2014
- AZD5363
- Olaparib
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborator